Malta Fever

Malta fever, more commonly known in veterinary medicine as brucellosis, is a bacterial infection caused primarily by Brucella canis in dogs, though other Brucella species including Brucella abortus, Brucella melitensis, and Brucella suis can occasionally infect canines. The disease derives its historical name from its initial identification on the island of Malta in the 1850s, where British military physicians recognized a pattern of febrile illness among soldiers and local goat populations. The term Malta fever, along with undulant fever and Mediterranean fever, originally referred to human infection with Brucella melitensis, but the name has been applied colloquially to brucellosis across species.

In dogs, Brucella canis is the species of primary concern and was first isolated and identified in 1966 from beagle colonies experiencing reproductive failure. Since its initial description, canine brucellosis has been recognized as a worldwide disease with particular prevalence in regions with large populations of stray or uncontrolled breeding dogs. The organism is a small, gram-negative, intracellular bacterium that has evolved sophisticated mechanisms for surviving within host macrophages, which allows it to establish chronic infection and evade the immune system.

The significance of Malta fever extends beyond its impact on individual dogs because of its zoonotic potential. Brucella canis can be transmitted from infected dogs to humans, though human infection with this species tends to be less severe than infection with other Brucella species. Nevertheless, the zoonotic risk makes canine brucellosis a public health concern and influences management decisions, particularly regarding whether to attempt treatment or consider euthanasia of infected animals.

Brucellosis in dogs is considered a reportable disease in many jurisdictions, meaning that veterinarians who diagnose the condition are required to notify public health or agricultural authorities. This reporting requirement reflects the broader implications of the disease for animal and human health and facilitates epidemiological surveillance and control efforts.

The economic and emotional impact of Malta fever is particularly significant in breeding operations, where the disease can cause devastating reproductive losses including spontaneous abortions, stillbirths, and infertility. Outbreaks in breeding kennels can result in the loss of entire litters and the permanent removal of valuable breeding animals from programs, making prevention and early detection critical priorities for professional breeders.

The causative agent of Malta fever in dogs is Brucella canis, an obligate intracellular pathogen that preferentially targets cells of the reticuloendothelial system, including macrophages and monocytes. The bacterium possesses several virulence factors that enable it to survive and replicate within phagocytic cells, including a smooth lipopolysaccharide coat that helps it resist intracellular killing mechanisms and modulate host immune responses to favor chronic persistence.

Transmission of Brucella canis occurs through several routes, with the most significant being direct contact with infected reproductive fluids. Vaginal discharge during and after abortion, placental tissues, and aborted fetuses contain extremely high concentrations of the organism. Male dogs shed the bacterium in semen, and venereal transmission during mating is a major route of spread, particularly in uncontrolled breeding environments. The concentration of organisms in semen can remain high for months to years after initial infection, making chronically infected males an ongoing source of transmission.

Oronasal exposure is another important transmission route, as dogs may become infected through licking or ingesting contaminated body fluids, including urine, vaginal secretions, or aborted materials. The organism can also be transmitted through contact with contaminated fomites, though Brucella canis is relatively fragile in the environment and is readily killed by common disinfectants, ultraviolet light, and desiccation. Environmental survival is generally limited to days to weeks under favorable conditions of moisture and moderate temperature.

Transmission through intact mucous membranes, including conjunctival, nasal, and oral mucosa, is well documented. Dogs in close-contact situations such as kennels, shelters, and breeding facilities are at elevated risk due to the multiple opportunities for exposure to infected body fluids. Percutaneous transmission through skin wounds or abrasions is also possible, and this route is particularly relevant to veterinary personnel and kennel workers who handle infected dogs or their tissues.

The incubation period following exposure typically ranges from one to four weeks before bacteremia develops, though the onset of clinical signs may be delayed considerably beyond initial bacteremia. Once established, the infection tends to become chronic, with the organism sequestering in lymphoid tissues, reproductive organs, and intervertebral discs, creating reservoirs from which intermittent bacteremia and shedding can occur for months to years.

The clinical manifestations of Malta fever in dogs vary considerably depending on the sex and reproductive status of the affected animal, the duration of infection, and the specific organ systems involved. Many infected dogs appear clinically normal for extended periods, which contributes to the insidious spread of the disease within populations, as apparently healthy dogs may be actively shedding the organism.

In intact female dogs, the hallmark clinical sign of brucellosis is late-term abortion, typically occurring between 45 and 59 days of gestation. Aborted puppies may appear partially autolyzed, and the dam may exhibit prolonged brownish-green vaginal discharge lasting for several weeks following the abortion. Some infected females may carry pregnancies to term but produce stillborn or weak puppies that fail to thrive. Conception failure and early embryonic death can also occur, presenting as apparent infertility in dogs that were previously fertile.

Intact male dogs with brucellosis frequently develop epididymitis and orchitis, which may be unilateral or bilateral. In the acute phase, the affected testicle and epididymis become swollen, painful, and warm to the touch. As the disease progresses to chronicity, testicular atrophy occurs due to immune-mediated destruction of the seminiferous tubules, resulting in decreased sperm production and quality. Infertility in chronically infected males is common and may be irreversible even after treatment. Scrotal dermatitis from self-trauma due to discomfort is frequently observed.

Non-reproductive clinical signs can occur in dogs of any sex or reproductive status. Discospondylitis, an infection of the intervertebral disc and adjacent vertebral endplates, is a well-recognized complication of brucellosis and may manifest as back pain, reluctance to move, stiffness, or neurological deficits if spinal cord compression occurs. Lymphadenopathy, particularly enlargement of the retropharyngeal, inguinal, and internal iliac lymph nodes, is a common finding that may be detected on physical examination or imaging.

Ocular manifestations including anterior uveitis, endophthalmitis, and retinal detachment have been reported in dogs with brucellosis, though these presentations are less common than reproductive or musculoskeletal involvement. Generalized signs such as intermittent fever, lethargy, exercise intolerance, and weight loss may occur but are often subtle and easily attributed to other causes. The characteristically undulating pattern of fever that gives the disease one of its alternative names, undulant fever, is more commonly described in human brucellosis than in canine cases.

Accurate diagnosis of Malta fever in dogs requires careful selection and interpretation of diagnostic tests, as no single test provides definitive results in all cases. The diagnostic approach typically begins with serologic screening and may progress to confirmatory testing using culture or molecular methods. Understanding the limitations of each test is essential for proper interpretation and clinical decision-making.

The rapid slide agglutination test (RSAT) is the most commonly used screening test for canine brucellosis. This test detects antibodies against Brucella canis in serum and provides results within minutes, making it practical for point-of-care use. However, the RSAT has significant limitations, including a substantial false-positive rate due to cross-reactivity with antibodies against other gram-negative bacteria such as Pseudomonas and Bordetella. For this reason, a positive RSAT result should always be confirmed with more specific testing before clinical decisions are made.

The agar gel immunodiffusion (AGID) test using cytoplasmic protein antigens is a more specific confirmatory serologic test that helps differentiate true positive results from false positives obtained on RSAT. The AGID test has higher specificity but lower sensitivity than the RSAT, meaning that some truly infected dogs may test negative, particularly in the early stages of infection before a robust antibody response has developed. The combination of RSAT screening followed by AGID confirmation provides a reasonable balance of sensitivity and specificity for routine diagnostic purposes.

Blood culture remains the gold standard for definitive diagnosis of brucellosis, as isolation of the organism from blood provides unequivocal evidence of active infection. However, bacteremia in chronically infected dogs can be intermittent, and a single negative blood culture does not rule out infection. Serial blood cultures collected over several weeks increase diagnostic sensitivity. Culture of the organism requires specialized laboratory facilities and biosafety precautions due to the zoonotic potential of Brucella species, and growth may take one to four weeks.

Polymerase chain reaction (PCR) testing has emerged as a valuable diagnostic tool that can detect Brucella DNA in blood and other clinical specimens with high sensitivity and specificity. PCR can identify the organism during periods when blood culture might be negative and provides results more rapidly than traditional culture methods. However, PCR availability may be limited to specialized veterinary diagnostic laboratories, and the test may detect DNA from nonviable organisms following treatment, complicating interpretation in the post-treatment monitoring period.

Treatment of Malta fever in dogs is challenging and controversial, primarily because no antibiotic regimen has been proven to reliably eliminate the organism from infected dogs. The intracellular nature of Brucella canis protects it from many antibiotics that achieve adequate extracellular concentrations but penetrate poorly into the phagocytic cells where the bacterium resides. This biological reality means that treatment can reduce clinical signs and decrease shedding but may not achieve true bacteriological cure.

The most commonly recommended treatment protocol involves a combination of a tetracycline-class antibiotic, typically doxycycline, with an aminoglycoside such as gentamicin or streptomycin. Doxycycline is administered orally at a dose of 5 milligrams per kilogram twice daily for a minimum of four to eight weeks, while the aminoglycoside is administered by injection during the first one to two weeks of therapy. The rationale for combination therapy is that the tetracycline provides sustained intracellular drug levels while the aminoglycoside offers synergistic bactericidal activity against both intracellular and extracellular organisms.

Alternative antibiotic protocols have been explored with varying degrees of success. Fluoroquinolones such as enrofloxacin have been used in combination with doxycycline, and some protocols incorporate triple antibiotic therapy using doxycycline, an aminoglycoside, and a fluoroquinolone. Minocycline has also been used as an alternative to doxycycline in some treatment protocols. Regardless of the specific regimen chosen, prolonged treatment duration of at least several weeks is necessary, and premature discontinuation increases the risk of relapse.

Neutering or spaying infected dogs is strongly recommended as an adjunct to antibiotic therapy. Surgical sterilization removes the reproductive organs where Brucella canis preferentially concentrates and replicates, thereby reducing the overall bacterial burden and eliminating a major source of organism shedding. Neutering alone does not cure the infection but significantly improves the likelihood of treatment success when combined with appropriate antibiotic therapy.

Post-treatment monitoring is essential and should include serial serologic testing and ideally blood cultures performed at regular intervals for at least three to six months following completion of antibiotic therapy. Serologic titers may remain positive for months after successful treatment, making interpretation challenging. Rising titers or positive blood cultures during the monitoring period indicate treatment failure and the need for retreatment or reassessment of the management plan.

The zoonotic potential of Brucella canis is an essential consideration in the management of Malta fever in dogs and significantly influences clinical decision-making, particularly regarding the advisability of treating versus euthanizing infected animals. While human infection with Brucella canis is generally considered less severe than infection with other Brucella species, it can still cause significant illness and should not be underestimated.

Human infection with Brucella canis most commonly occurs through direct contact with infected reproductive fluids, urine, or blood from infected dogs, particularly through mucous membrane exposure or breaks in the skin. Occupational risk groups include veterinarians, veterinary technicians, kennel workers, dog breeders, and laboratory personnel who handle clinical specimens. Household exposure from pet dogs has also been documented, particularly in settings where infected dogs have given birth or aborted in the home environment.

Clinical manifestations of Brucella canis infection in humans are variable and may include intermittent fever, fatigue, malaise, headache, weight loss, and musculoskeletal pain. More serious complications such as endocarditis, osteomyelitis, and meningoencephalitis have been reported but are uncommon. The nonspecific nature of symptoms means that human brucellosis is frequently underdiagnosed, and healthcare providers may not consider the diagnosis unless they are aware of the patient's exposure to infected dogs.

Immunocompromised individuals, including those with HIV/AIDS, those receiving chemotherapy or immunosuppressive therapy, transplant recipients, pregnant women, and young children, face elevated risk of more severe disease if exposed to Brucella canis. In households containing high-risk individuals, the decision to attempt treatment of an infected dog must be weighed very carefully against the ongoing zoonotic risk, and in many cases, veterinary and public health authorities may recommend euthanasia as the safest option.

Preventive measures for people who are in contact with infected dogs include wearing gloves and protective clothing when handling the animal or cleaning areas potentially contaminated with body fluids, practicing thorough hand hygiene after contact, and avoiding exposure to reproductive secretions, urine, and blood. All family members should be informed of the diagnosis and the associated risks, and household contacts who develop compatible symptoms should be referred to their physician with notification of the potential brucellosis exposure.

Malta fever poses a catastrophic threat to dog breeding operations, where the disease can spread rapidly through a population and cause devastating reproductive losses before it is even recognized. The management of brucellosis outbreaks in breeding kennels requires a systematic approach that encompasses testing, isolation, treatment or culling decisions, environmental decontamination, and long-term surveillance.

The introduction of an infected dog into a breeding facility is the most common initiating event for kennel outbreaks. This may occur when a new dog is added to the program without adequate pre-entry testing, when a dog returns from an outside breeding without having been tested, or when a stray or rescue dog is brought into proximity with breeding animals. The insidious nature of the disease, with its potential for subclinical carriage and intermittent shedding, means that an infected animal can circulate within a breeding population for weeks to months before clinical signs prompt diagnostic investigation.

When an outbreak is identified, immediate management steps include serologic testing of all dogs in the facility, strict isolation of positive or suspect animals, and cessation of all breeding activities until the extent of the outbreak has been characterized. Testing should be repeated at 30-day intervals to identify newly seroconverting animals that may have been in the incubation period during initial testing. Dogs that test positive on confirmed serologic tests should be permanently removed from breeding programs regardless of whether treatment is attempted.

The economic impact of a brucellosis outbreak on a breeding operation can be enormous. Direct losses include aborted litters, veterinary diagnostic and treatment costs, and the removal of affected dogs from breeding programs. Indirect costs include the suspension of breeding activities during the outbreak management period, potential loss of reputation, and the long-term impact on genetic planning if key breeding animals must be removed. Insurance coverage for infectious disease losses may be limited or unavailable, adding to the financial burden.

Prevention within breeding programs centers on rigorous testing protocols. All dogs should be tested for brucellosis before any breeding, whether natural or artificial insemination. New dogs entering a kennel should be quarantined and tested at least twice, with 30 days between tests, before being introduced to the resident population. Dogs being sent to outside breedings or received for breeding should have current negative test results, ideally within the preceding 30 days.

The decision to manage a dog diagnosed with Malta fever in a household setting is complex and involves balancing the welfare of the infected dog, the safety of other animals in the household, and the zoonotic risk to human family members. If the decision is made to pursue treatment rather than euthanasia, a comprehensive management plan must be developed and strictly followed to minimize risks to all household members.

Infected dogs should be surgically sterilized as soon as their clinical condition permits, as this is a critical component of both treatment and risk reduction. Following sterilization, the dog should be maintained on the prescribed antibiotic protocol for the full recommended duration, with no premature discontinuation even if the dog appears to have improved clinically. Compliance with the treatment regimen is essential, and owners should be prepared for the financial commitment of prolonged antibiotic therapy and serial follow-up testing.

Household hygiene measures must be implemented diligently. Infected dogs should not be allowed to lick people's faces or open wounds. Urine should be cleaned promptly with disinfectant, and any areas where the dog urinates or rests should be cleaned regularly with a solution effective against Brucella, such as a ten percent bleach solution or quaternary ammonium compound. All bedding used by the infected dog should be washed frequently in hot water, and food and water bowls should be cleaned separately from household dishes.

If other dogs are present in the household, the infected dog should be kept separate, particularly from intact animals. All other dogs in the household should be tested for brucellosis, and repeat testing should be performed at 30-day intervals for at least three months following the last possible exposure. Introducing new dogs into a household with a known infected dog is not recommended until the infected dog has been confirmed free of the organism through serial negative testing following completion of treatment.

Ongoing monitoring of the treated dog includes serial serologic testing and ideally blood cultures at three-month intervals for a minimum of one year following treatment completion. Owners must understand that apparent clinical recovery does not guarantee bacteriological cure, and that the dog may require retreatment if monitoring indicates persistent or recurrent infection. The emotional burden of managing a chronically infected pet can be significant, and veterinary teams should provide supportive communication throughout the extended management period.

Timely veterinary consultation is essential for any dog suspected of having Malta fever, whether based on clinical signs, known exposure to an infected animal, or as part of routine pre-breeding screening. Because early diagnosis is critical for preventing transmission and managing the disease effectively, owners and breeders should be aware of the circumstances that warrant immediate veterinary attention.

Any intact female dog that experiences a late-term abortion or delivers stillborn puppies should be evaluated for brucellosis as part of the diagnostic workup. The presence of brownish-green vaginal discharge persisting for more than one to two weeks following whelping or abortion is also cause for concern. While there are many causes of canine reproductive failure, brucellosis must be ruled out given its implications for the individual dog, other dogs in the household or kennel, and potentially for human household members.

Intact male dogs presenting with testicular swelling, pain, or progressive atrophy should be tested for brucellosis, particularly if they are used for breeding. Declining semen quality identified during breeding soundness evaluations should also prompt testing. Scrotal dermatitis in intact males, while having many possible causes, can be associated with the discomfort of epididymitis or orchitis caused by Brucella canis.

Dogs presenting with back pain, reluctance to move, or progressive stiffness should be evaluated for discospondylitis, which is a well-known sequela of brucellosis. Radiographic or advanced imaging findings consistent with discospondylitis should trigger brucellosis testing as part of the investigation into the underlying cause, even in neutered dogs, as the organism can persist in the intervertebral discs long after sterilization.

Any dog that has had contact with a known positive animal should be tested regardless of whether clinical signs are present. This includes dogs housed in the same facility, dogs that have mated with a positive animal, and dogs that may have been exposed to body fluids from an infected animal. Testing should be performed immediately upon discovery of the exposure and repeated at 30-day intervals for at least 90 days to account for the incubation period and the time required for seroconversion.

Prevention of Malta fever relies on a combination of testing protocols, biosecurity measures, and responsible breeding practices, as there is currently no commercially available vaccine for Brucella canis in dogs. A comprehensive prevention strategy must address the risk of introducing infection into a population, the detection of subclinical carriers, and the management of environmental contamination.

Routine serologic testing is the foundation of brucellosis prevention in breeding populations. All dogs intended for breeding should be tested within 30 days prior to each mating event. This recommendation applies to both the sire and dam and regardless of whether natural mating or artificial insemination is planned, as both routes can facilitate transmission. Annual testing of all dogs in a breeding program, even those not currently being bred, provides an additional layer of surveillance and can identify subclinical infections before they result in outbreaks.

Quarantine and testing of new arrivals is a critical biosecurity measure for any kennel or breeding facility. New dogs should be physically isolated from the resident population for a minimum quarantine period of 30 days, during which at least two serologic tests should be performed with negative results before integration. This protocol accounts for the possibility that a newly acquired dog may be in the incubation period of infection, during which a single serologic test might fail to detect antibodies that have not yet reached detectable levels.

Environmental management and sanitation contribute to reducing the risk of indirect transmission. While Brucella canis is not particularly hardy in the environment, it can survive for several weeks in moist, cool conditions away from direct sunlight. Regular cleaning and disinfection of kennel surfaces, whelping areas, and exercise areas using effective disinfectants reduces the environmental load of the organism. Proper disposal of reproductive tissues, including placentas, aborted materials, and vaginal discharge, is essential for preventing environmental contamination and exposure of other animals and personnel.

Public health education is an important component of prevention, particularly for individuals involved in dog breeding, rescue, or veterinary care. Awareness of the zoonotic risk, understanding of transmission routes, and knowledge of appropriate protective measures empower individuals to make informed decisions about their interaction with dogs of unknown brucellosis status. Veterinary practices should include brucellosis education in their client communication materials, particularly for clients involved in breeding activities or those who acquire dogs from high-risk sources such as shelters, rescues, or international adoptions.